Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Twist Bioscience's 3-Year RORE % for the quarter that ended in Mar. 2026 was -23.93%.
The industry rank for Twist Bioscience's 3-Year RORE % or its related term are showing as below:
MIL:1TWST's 3-Year RORE % is ranked worse than 61.11% of 198
companies
in the Medical Diagnostics & Research industry
Industry Median: -8.425
vs MIL:1TWST: -23.93
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Twist Bioscience 3-Year RORE % Related Terms
Twist Bioscience 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Twist Bioscience's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1TWST vs BLLN, SHC, RDNT: 3-Year RORE % Comparison
For the Diagnostics & Research subindustry, Twist Bioscience's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience 3-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Twist Bioscience (MIL:1TWST) has a 3-Year RORE % of -23.93 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Twist Bioscience and its competitors. According to the industry distribution chart, Twist Bioscience ranks #121 out of 198 companies in the Medical Diagnostics & Research industry, placing it in the top 61.1%.
Is Twist Bioscience's 3-Year RORE % too high?
Twist Bioscience's current 3-Year RORE % is -23.93. Based on the distribution chart, Twist Bioscience ranks #121 out of 198 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Twist Bioscience has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's 3-Year RORE % compare to BLLN and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Twist Bioscience ranks #121 out of 198 companies for 3-Year RORE %. This places Twist Bioscience in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Twist Bioscience and its competitors. Twist Bioscience's current 3-Year RORE % is -23.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (MIL:1TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is €46.60, compared to a current price of €97.44 — trading 109.1% above its estimated fair value. The current 3-Year RORE % is -23.93. Twist Bioscience's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Twist Bioscience (MIL:1TWST), the current 3-Year RORE % is -23.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (MIL:1TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of €97.44 is trading 109.1% above its estimated GF Value™ of €46.60.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for MIL:1TWST:
3-Year RORE %: -23.93
GF Value™: €46.60 vs. price of €97.44 (109.1% above fair value)
No single metric tells the full story. See the MIL:1TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
47GF Score
Get the complete analysis for MIL:1TWST
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1TWST has been successfully added to your 
